Provider treatment intensity and outcomes for patients with early-stage bladder cancer

Journal of the National Cancer Institute

Volumn 101, Issue 8, 2009, Pages 571-580

  Hollenbeck, Brent K ^a   Ye, Zaojun ^a   Dunn, Rodney L ^a   Montie, James E ^a   Birkmeyer, John D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; EARLY CANCER; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLADDER TUMOR; CANCER REGISTRY; CANCER STAGING; CLINICAL PRACTICE; CONFIDENCE INTERVAL; COST OF ILLNESS; CYSTOSCOPY; ECONOMICS; INTRAVESICAL DRUG ADMINISTRATION; MEDICAL RECORD; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; STATISTICS; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENT;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CONFIDENCE INTERVALS; COST OF ILLNESS; CYSTOSCOPY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAL RECORD LINKAGE; MEDICARE; NEOPLASM STAGING; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 64749102020     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp039     Document Type: Article

References (37)

1. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995;33(8):828-841.
2. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol. 2003;169(5):1697-1701.
3. Haukaas S, Daehlin L, Maartmann-Moe H, Ulvik NM. The long-term outcome in patients with superfi cial transitional cell carcinoma of the bladder:a single-institutional experience. BJU Int. 1999;83(9):957-963.
4. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Busch C, Johansson SL. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999;162(3 pt 1):702-707.
5. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995;153(6):1823-1826;discussion 1826-1827.
6. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary(TaG3) bladder tumors:15-year outcome. J Urol. 2000;163(1):60-61.
7. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer:long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
8. Dimopoulos MA, Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol. 1998 ;16(4):1601-1612.
9. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer(stages Ta, T1, and Tis):2007 update. J Urol. 2007;178(6):2314-2330.
10. The National Comprehensive Cancer Network. Bladder Cancer V.2.2008. http://www.nccn.org/professionals/physician-gls/PDF/bladder.pdf. Accessed June 4, 2008.
11. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data:content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-18.
12. Surveillance, Epidemiology, and End Results(SEER) Program. http:// seer.cancer.gov/. Accessed December 12, 2006.
13. Greene FL, Page EL, Fleming ID. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
14. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superfi cial bladder cancer. J Natl Cancer Inst. 2003;95(8):588-597.
15. US Public Health Service. International Classifi cation of Diseases, 9th revision.(PHS) 92-1260. Washington, DC:US GPO;1992.
16. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-104-17.
17. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superfi cial bladder tumors? J Urol. 2001;166(4):1296-1299.
18. Stein JP. Indications for early cystectomy. Semin Urol Oncol. 2000;18(4):289-295.
19. American Medical Association. Current Procedure Terminology. CPT 2005, Standard Edition. Chicago, IL: AMA Press;2004.
20. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8 suppl):IV-19-25.
21. Hoel DG, Ron E, Carter R, Mabuchi K. Infl uence of death certifi cate errors on cancer mortality trends. J Natl Cancer Inst. 1063;85(13):1063-1068.
22. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series:interpreting trends in prostate cancer - part II: cause of death misclassifi cation and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999 ;91(12):1025-1032.
23. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer:are death certifi cates valid? J Natl Cancer Inst. 2001;93(23):1822-1823.
24. Weinstock MA, Reynes JF. Validation of cause-of-death certifi cation for outpatient cancers:the contrasting cases of melanoma and mycosis fungoi-des. Am J Epidemiol. 1998;148(12):1184-1186.
25. World Health Organization. International Classifi cation of Diseases for Oncology, Second Edition. Geneva: World Health Organization;1990.
26. Diez Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease [see comment]. N Engl J Med. 2001;345(2):99-106.
27. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies:development and validation. J Chronic Dis. 1987;40(5):373-383.
29. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes [see comment]. Ann Intern Med. 2003;139(8):658-665.
30. Lin DY. Cox regression analysis of multivariate failure time data:the marginal approach. Stat Med. 1994;13(21):2233-2247.
31. Kleinbaum D. Evaluating the proportional hazards assumption. In:Diez K, Gail M, Krickeberg K, Singer B, eds. Survival Analysis. New York:Springer;1996:129-166.
32. Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors:a randomized controlled trial. Scand J Urol Nephrol Suppl. 1995;172:33-36.
33. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167(4):1573- 1583.
34. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2003(3):CD003231.
35. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias:effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;97(3):278-285.
36. Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? [comment]. JAMA. 2001;286(10):1228-1230.
37. Heney NM, Nocks BN, Daly JJ, et al. Ta and T1 bladder cancer:location, recurrence and progression. Br J Urol. 1982;54(2):152-157.